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Abstract Interleukin-6 (IL-6) production is up-regulated by
several stimuli through the activation of transcription factors.
We have previously demonstrated that CCAAT/enhancer bind-
ing protein homologous protein (CHOP) positively regulates
IL-6 production at the transcriptional level in the human mela-
noma cell line A375. In this study, we provide evidence that
CHOP up-regulates the IL-6 transcription without binding to
the IL-6 promoter. CHOP dimerized more preferentially with
an inhibitory isoform of nuclear factor for IL-6 expression (LIP
(liver-enriched inhibitory protein)) than with a positively acting
isoform (LAP, liver-enriched activator protein). These results
indicate that CHOP plays an important role in IL-6 production
without binding to its promoter, probably by trapping protein(s)
such as LIP, which would otherwise inhibit IL-6 transcription.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Interleukin-6 (IL-6) is a multifunctional cytokine that reg-
ulates T cell proliferation [1], B cell di¡erentiation [2], and
induction of acute phase proteins [3], and is involved in var-
ious autoimmune diseases such as chronic rheumatoid arthri-
tis [4]. The human IL-6 gene has been isolated [5] and the
350-bp region upstream from the transcription initiation site
was found to exhibit strong similarity to the cognate mouse
sequence. Several transcriptional regulatory elements were
identi¢ed in this region. By using deletion mutants of the
IL-6 promoter region, an IL-1 responsive element was found
at position 3180 to 3122 [6], and a 14-bp palindromic DNA
motif (ACATTGCACAATCT) in this region was identi¢ed as
a binding site for nuclear factor for IL-6 expression (NF-IL6)
(C/EBPL), a member of the CCAAT/enhancer binding protein
(C/EBP) family of transcription factors. In this region, be-
tween 3173 and 3151, lies a 23-bp DNA element termed
multiple responsible element, which is essential for the induc-
tion of IL-6 transcription by treatment with IL-1, tumor ne-
crosis factor (TNF), forskolin, or phorbol ester. Moreover, an
activator protein 1 (AP-1) binding motif upstream of this
region and a nuclear factor UB (NF-UB) binding motif lying
downstream are also involved in IL-6 production by IL-1 or
TNFK [4].
NF-IL6 has been initially identi¢ed as a factor that binds to
the IL-6 promoter region and enhances expression of IL-6
when hepatocytes are treated with IL-1 [7]. NF-IL6 is a mem-
ber of the C/EBP family of transcription factors. All C/EBP
family members possess a basic leucine zipper domain in their
carboxyl-terminal region, with which they form homo- or het-
erodimers. This dimerization is essential for binding to pro-
moter DNA to activate transcription. Normally, NF-IL6
mRNA is not expressed, but is markedly induced in response
to infection or in£ammation in almost all tissues [7]. NF-IL6
responsive elements are found in several cytokine genes (IL-1,
IL-6, IL-8, TNFK, and granulocyte colony stimulating factor
(G-CSF)) and acute phase proteins (haptoglobin, C-reactive
protein (CRP), K1-acid glycoprotein), and NF-IL6 plays mul-
tiple roles in various tissues [8].
Three isoforms of NF-IL6 (C/EBPL) are generated from a
single mRNA through the use of di¡erent translation initia-
tion sites and a leaky ribosomal scanning mechanism [9,10].
All of these isoforms possess a common carboxyl-terminal
portion, and therefore they can form dimers and subsequently
bind to C/EBP binding elements. Among these isoforms, the
translation product initiated at the third AUG (LIP (liver-
enriched inhibitory protein)) is devoid of the transcription-
activation domain located in the amino-terminal portion of
the translation product initiated at the ¢rst or second AUG
(LAP (liver-enriched activator protein)), and consequently the
former product stimulates transcription much less e⁄ciently
than the latter two products [9,10].
C/EBP homologous protein (CHOP), a member of the
C/EBP family of transcription factors, was originally isolated
as the gene induced in response to DNA damage agents [11] ;
subsequently it has been revealed that CHOP is induced by
various extracellular or endoplasmic reticulum stresses [12^
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17]. By forming heterodimers with other C/EBP family pro-
teins such as NF-IL6, CHOP inhibits their DNA binding
activity and transactivational ability [18]. The basic region
of CHOP is less conserved than that of other C/EBP family
proteins. Actually, at ¢rst, CHOP was thought to lack DNA
binding activity. Interestingly, however, a CHOP^C/EBP het-
erodimer has been reported to bind to a unique DNA se-
quence di¡erent from classical C/EBP binding sites and to
act as a transactivator [19].
Recently, we demonstrated up-regulation of IL-6 promoter
activity by CHOP in a manner dependent on the leucine zip-
per domain [20]. However, as described above, CHOP is re-
ported to interfere with the transcriptional activity of NF-IL6
that contributes to IL-6 transcription. Therefore, these obser-
vations are inconsistent. In this study, we demonstrate that
CHOP mediates the activation of IL-6 promoter by a novel
mechanism, trapping negative regulating isoform of NF-IL6.
2. Materials and methods
2.1. Reagents
RPMI 1640 and Dulbecco’s modi¢ed Eagle’s medium were pur-
chased from Sigma (St. Louis, MO, USA). Fetal bovine serum was
from JRH Bioscience (Lenexa, KS, USA), anti-Flag monoclonal anti-
body (M2) from Sigma, and anti-NF-IL6 polyclonal antibody (C-19)
from Santa Cruz (Santa Cruz, CA, USA).
2.2. Cell culture
The human melanoma cell line A375, the human embryonic kidney
cell line 293, and the human hepatocellular carcinoma cell line HepG2
were cultured as described previously [21].
2.3. Plasmid construction
The plasmid pcDNA3.1-Flag-CHOP, leading to a fusion of the
Flag epitope tag to the amino-terminus of human CHOP, was con-
structed as described previously [21]. The entire coding region of
human CHOP was subcloned into pGEX-4T-1 (Amersham Bio-
science, Little Chalfont, UK). pCMV-Flag-NFIL6 and pCMV-Flag-
NFIL6 vSpl were constructed by ligating NF-IL6 or NF-IL6 vSpl
cDNA from pEF-NFIL6 or pEF-NFIL6 vSpl [22], kindly provided
by Dr. S. Akira (Osaka University, Japan) with pCMV-Tag2 (Stra-
tagene, La Jolla, CA, USA). pIL6(31165)-Luc plasmid, an Asp718/
XhoI fragment containing the 1174-bp (31165 to +9 relative to the
transcription initiation site) 5P-upstream sequence of the human IL-6
gene, was prepared as described previously [20]. For other series of
reporter genes with deletion mutants of the 5P-£anking region of the
IL-6 gene, pIL6(3835)-Luc and pIL6(3231)-Luc, each fragment of
5P-upstream region of IL-6 gene obtained by polymerase chain reac-
tion (PCR) from pIL6(31165)-Luc was ligated with pGL3-basic
(Promega, Madison, WI, USA). To obtain p(C/EBP)4-Luc, four tan-
dem repeats of C/EBP binding elements in the 5P-upstream region of
the IL-6 gene were ampli¢ed by PCR and ligated with pGL3-basic.
All constructs were veri¢ed by sequencing.
pUB4-Luc was kindly provided by Dr. T. Okamoto (Nagoya City
University, Japan).
2.4. Transfection
A375 cells were transfected using E¡ectene (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions. 293 and HepG2
cells were transfected by the Chen^Okayama method [23].
2.5. Assay for IL-6 promoter activity
A375 cells were transiently co-transfected with each pIL6-Luc plas-
mid, pCMV-L-gal, and plasmids as described in the ¢gure legends in a
six-well plate. One day later, the medium was changed. After 24 h,
luciferase activity was assayed as described previously [20].
2.6. Chromatin immunoprecipitation (ChIP) assay
ChIP was performed according to the method of Masternak et al.
with slight modi¢cation [24]. 293 cells were transiently transfected
with pcDNA3.1-Flag-CHOP or pCMV-Flag-NFIL6. Two days later,
the cells were cross-linked with 1% formaldehyde. Immunoprecipi-
tated DNA was analyzed by PCR using the following primers speci¢c
for the IL-6 promoter: sense 5P-AGTGGTGAAGAGACTCAGTG-3P
and antisense 5P-GGCAGAATGAGCCTCAGA-3P. The PCR prod-
ucts were analyzed by agarose gel electrophoresis followed by ethid-
ium bromide staining.
2.7. Promoter pull-down assay
By using PCR with a biotinylated primer and each pIL6-Luc plas-
mid, the promoter templates were biotinylated at the 5P-end of the
lower strand. 293 cells were transiently transfected with pcDNA3.1-
Flag-CHOP or pCMV-Flag-NFIL6. After 2 days, cells were lysed in
RIPA bu¡er (0.1% SDS, 0.5% deoxycholate, 1% Triton X-100, 150
mM NaCl, 50 mM Tris^HCl at pH 8.0, and protease inhibitors). Cell
extracts were supplemented with 0.1 mg/ml poly(dI-dC) and incubated
with 2 pmol of biotinylated IL-6 promoter fragments for 2 h at 4‡C.
Streptavidin-conjugated magnetic particles (50 Wg; Promega) were
then added and incubated for an additional 1 h. The particles were
washed four times with TNTE bu¡er (20 mM Tris^HCl at pH 7.4,
150 mM NaCl, 0.1% Triton X-100, 1 mM EDTA) and proteins were
eluted with sodium dodecyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE) sample bu¡er followed by Western blotting analysis.
2.8. Expression of recombinant CHOP protein and glutathione
S-transferase (GST) pull-down assay
GST-tagged CHOP protein was expressed in Escherichia coli DH5K
and a⁄nity-puri¢ed with glutathione-Sepharose 4B (Amersham Bio-
science). The purity and concentration of the recombinant protein
were estimated by Coomassie brilliant blue staining.
A375 cells were lysed in RIPA bu¡er. Aliquots of cell extracts were
mixed with GST or GST-CHOP; protein^protein complexes were
allowed to form for 1 h at 4‡C, and then incubated with gluta-
thione-Sepharose beads for an additional 1 h. The beads were washed
four times with TNTE bu¡er, and proteins were eluted with SDS^
PAGE sample bu¡er followed by Western blotting analysis.
2.9. Immunoprecipitation and Western blotting
Cells were transiently transfected and treated as described in the
¢gure legends. The cells were lysed in RIPA bu¡er. The lysates were
subjected to immunoprecipitation with anti-Flag antibody. One to ¢ve
percent of lysates and immunoprecipitates were subjected to SDS^
12.5% PAGE, transferred onto PVDF membranes and probed with
antibody(s) described in the ¢gure legends. The immunoreactive pro-
teins were visualized by ECL Western blotting detection reagents
(Amersham Bioscience), and the light emission was quanti¢ed with
a Lumino image analyzer LAS-1000 (FUJI, Japan).
3. Results
3.1. Determination of CHOP responsive elements in the
5P-£anking region of the IL-6 gene
We have previously observed that CHOP up-regulates IL-6
promoter activity without any stimulation or treatment [20].
To determine the 5P-cis-regulatory element(s) involved in the
stimulatory e¡ect of CHOP, we generated 5P-deletion mutants
of the IL-6 promoter and ligated them into luciferase reporter
plasmids. Each reporter plasmid and the CHOP expression
plasmid were transiently co-transfected into human melanoma
cell line A375, and then the luciferase activity in the cell ly-
sates was measured. Transfection of CHOP considerably up-
regulated the luciferase activity in comparison with mock
transfection (Fig. 1A). The luciferase activity was signi¢cantly
increased when the region from 31165 to 3835 bp was de-
leted, suggesting that a repressor-like factor may a¡ect or a
silencer-like element may exist in this region. Even in this case,
a stimulatory e¡ect of CHOP on the promoter activity was
observed. The luciferase activity was not further changed
upon further deletion of the upstream region to 3231 bp,
even though this deletion removed a putative AP-1 responsi-
ble element. In addition, this 3231 region, containing NF-IL6
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and NF-UB binding elements, maintained responsiveness to
CHOP. Because CHOP readily dimerizes with other C/EBP
family members containing NF-IL6 [18], we focused on the
NF-IL6 responsive element in this region. To assess whether
this element is critical for the CHOP-dependent activation of
IL-6 transcription, we further constructed an NF-IL6-lucifer-
ase reporter gene containing four putative NF-IL6 binding
sites derived from the IL-6 promoter region. As shown in
Fig. 1B, overexpression of CHOP produced an increase of
luciferase activity comparable to that seen with NF-IL6 in
A375 cells. On the other hand, with an NF-UB reporter
gene (pUB4-Luc), no activation by CHOP was observed, and
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Fig. 1. Deletion analysis of the 5P-£anking region of the human IL-6 gene in A375 cells. A: Putative consensus sequences in the 5P-upstream re-
gion of the human IL-6 gene fused with luciferase cDNA are illustrated. Numbers indicate distance in base pairs from the transcription start.
Each pIL6-Luc reporter plasmid (0.02 Wg), L-galactosidase plasmid (0.04 Wg) and pcDNA3.1-Hygro (open column) or pcDNA3.1-Myc/hCHOP
(closed column) (0.4 Wg each) was transiently co-transfected into A375 cells. B: A reporter plasmid containing tandem repeats of a putative
C/EBP binding site in the 5P-upstream region of the human IL-6 gene, fused to luciferase cDNA (0.02 Wg), L-galactosidase plasmid (0.04 Wg)
and pcDNA3.1-Hygro (open column) (0.4 Wg), pcDNA3.1-Myc/hCHOP (gray column) (0.4 Wg) or pCMV-Flag-NFIL6 (0.04 Wg) (closed col-
umn) were transiently co-transfected into A375 cells. Plasmid pGL3-promoter was transfected as a control. The relative promoter activity indi-
cates the ratio between the luciferase activity in mock transfectants and those in others after the normalization with L-galactosidase activity ex-
pression. MeanTS.D. based on triplicate cultures is shown.
Fig. 2. CHOP does not bind to the promoter region of the IL-6 gene. A: Cross-linked chromatin isolated from 293 cells transfected with
pcDNA3.1-Hyg, pcDNA3.1-Flag-CHOP, or pCMV-Flag-NFIL6 (2 Wg each) was immunoprecipitated with antibody against Flag-tag. Immuno-
precipitates were analyzed by PCR to con¢rm the presence of promoter sequence of the human IL-6 gene. B,C: Recruitment of C/EBP family
protein to IL-6 promoter fragments dependent on NF-IL6 binding element. 293 cells were transiently transfected with pcDNA3.1-Hyg (2 Wg),
pcDNA3.1-Flag-CHOP (2 Wg), or pCMV-Flag-NFIL6 (0.2 Wg). Cell extracts (input) were subjected to pull-down assay as described in Section 2.
(C/EBP)4 represents four tandem repeats of the putative NF-IL6 binding element (located at position 3163 to 3150).
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deletion of the NF-UB binding site from the pIL6(3835)-Luc
reporter gene exhibited the same stimulatory response to
CHOP as did the wild-type reporter gene (data not shown).
These results were also observed in human embryonic kidney
cell 293 cells and suggest that CHOP-induced IL-6 promoter
activation could be dependent on the promoter’s NF-IL6 re-
sponse element.
3.2. CHOP is not recruited to the IL-6 promoter region
By using CHOP mutants, we have previously demonstrated
that dimerization ability is important for activation of IL-6
promoter by CHOP [20]. Thus, it was expected that dimeri-
zation of CHOP with other C/EBP family proteins would be
required for IL-6 promoter activation rather than binding to
and transactivating the IL-6 promoter. To determine whether
CHOP is physically associated with the IL-6 promoter in liv-
ing cells, we next performed ChIP assay. For this experiment
it was necessary to use 293 cells, because of their high trans-
fection e⁄ciency. Cross-linked chromatin fragments were iso-
lated from 293 cells transfected with Flag-tagged CHOP or
NF-IL6, immunoprecipitated with antibody against Flag-tag,
and analyzed by PCR for the presence of speci¢c DNA se-
quence corresponding to the IL-6 promoter. As shown in Fig.
2A, IL-6 promoter sequences were immunoprecipitated with
anti-Flag antibody only from Flag-NF-IL6-transfected cells,
but not from Flag-CHOP-transfected cells. To con¢rm the
result of the ChIP assay, we examined in vitro binding of
these C/EBP proteins to IL-6 promoter sequence by promoter
pull-down assay. IL-6 promoter templates of various lengths
were immobilized on magnetic beads and cell extracts from
293 cells transiently transfected with Flag-NF-IL6 or Flag-
CHOP were assessed in a ‘pull-down’ assay by using an
anti-Flag antibody. NF-IL6 bound to IL-6 promoter tem-
plates containing the upstream region from 3835 to +9
(Fig. 2B). NF-IL6 also bound to promoter template contain-
ing the 3231-bp upstream region. Furthermore, NF-IL6
bound to the (C/EBP)4 sequence, which has four tandem re-
peats of NF-IL6 binding elements as found in the IL-6 pro-
moter, while CHOP did not bind to any IL-6 promoter tem-
plates at all (Fig. 2C). These ¢ndings suggest that NF-IL6 but
not CHOP binds to NF-IL6 responsive element in the IL-6
promoter.
3.3. CHOP preferentially associates with a negatively
regulating NF-IL6 isoform, NF-IL6 3rd AUG, rather than
with positively regulating isoforms
The results above suggested that CHOP up-regulates IL-6
transcription without interacting with the IL-6 promoter re-
gion. Accordingly, we hypothesized that CHOP regulates the
activity of NF-IL6, which in turn binds to the IL-6 promoter
region and activates IL-6 transcription. To examine this pos-
sibility, cell extracts from A375 cells were subjected to GST
pull-down by using GST or GST-CHOP and associated en-
dogenous NF-IL6 isoforms were detected by immunoblotting
using an anti-NF-IL6 antibody recognizing its C-terminal re-
gion. Compared with the amount of each NF-IL6 isoform in
input cell extracts, GST-CHOP bound almost solely the ami-
no-terminal truncated isoform of NF-IL6, NF-IL6 3rd AUG,
which has no transcriptional activity (Fig. 3A). These results
were also observed in HepG2 and 293 cells (data not shown).
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Fig. 3. CHOP preferentially dimerizes with a negatively regulating isoform of NF-IL6, NF-IL6 3rd AUG. A: Cell extracts (input) from A375
cells were subjected to pull-down analysis with recombinant GST-CHOP immobilized on glutathione-Sepharose beads. Proteins associated with
GST-CHOP were puri¢ed and then analyzed by immunoblotting with anti-NF-IL6 C-terminal antibody. B: HepG2 cells were transiently trans-
fected with pcDNA3.1-Flag-CHOP or empty vector (10 Wg each). After 2 days, cell extracts (input) were subjected to immunoprecipitation (IP)
with anti-Flag antibody. Whole extracts and precipitates were analyzed by immunoblotting (IB) using anti-Flag or anti-NF-IL6 C-terminal anti-
body.
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To examine in vivo association of endogenous NF-IL6 iso-
forms with CHOP, we subjected cell extracts from HepG2
cells, transiently transfected with Flag-CHOP, to immunopre-
cipitation with an anti-Flag antibody and then analyzed the
precipitate by immunoblotting using an anti-NF-IL6 anti-
body. As in the GST pull-down assay, CHOP preferentially
associated with NF-IL6 3rd AUG, rather than with NF-IL6
1st or 2nd AUG (Fig. 3B). These results indicated that CHOP
preferentially associates with the transcriptionally inactive
NF-IL6 isoform, NF-IL6 3rd AUG, rather than with the
transcriptionally active NF-IL6 1st or 2nd AUG isoforms.
3.4. CHOP activates IL-6 transcription by releasing NF-IL6
3rd AUG from the IL-6 promoter
Because the CHOP^C/EBP heterodimer could not bind
classical a C/EBP binding motif [18], and because CHOP
preferentially associated with NF-IL6 3rd AUG, we next in-
vestigated by promoter pull-down assay whether CHOP alters
the pro¢le of NF-IL6 isoforms that bind to the IL-6 promoter
region. In the absence of CHOP, all endogenous NF-IL6 iso-
forms bound to IL-6 promoter template in the same propor-
tion as in the input extract (Fig. 4A, lanes 1 and 2). In con-
trast, when recombinant CHOP protein was added to the
assay system, NF-IL6 3rd AUG was remarkably removed
from the IL-6 promoter template without any changes in
NF-IL6 1st AUG and 2nd AUG binding to the IL-6 pro-
moter template (Fig. 4A, lane 3). To determine whether
CHOP recovers the IL-6 transcription down-regulated by
NF-IL6 3rd AUG, we carried out reporter gene assay using
pIL6(3231)-Luc. As shown in Fig. 4B, the luciferase activity
was increased by co-transfection with NF-IL6. NF-IL6 vSpl,
which mimics NF-IL6 3rd AUG [22], inhibited IL-6 promoter
activity up-regulated by NF-IL6. As expected, when CHOP
was co-transfected, down-regulation of IL-6 promoter activity
induced by NF-IL6 vSpl was recovered to levels comparable
to those seen after transfection with NF-IL6 alone. These
observations suggest that CHOP up-regulates IL-6 transcrip-
tion by eliminating from the IL-6 promoter dimers comprising
NF-IL6 3rd AUG together with NF-IL6 1st or 2nd AUG-
NF-IL6.
Finally we examined the dose^response e¡ect of CHOP ex-
pression on IL-6 transcription in A375 cells. As shown in Fig.
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Fig. 4. CHOP activates IL-6 transcription by removing NF-IL6 3rd
AUG from IL-6 promoter. A: HepG2 cell extracts were subjected
to promoter pull-down assay as described in Fig. 2 using a DNA
template corresponding to an IL-6 promoter fragment containing
240 bp (3231 to +9 relative to the transcription initiation site) in
the absence or presence of 5 Wg GST-CHOP and then analyzed by
immunoblotting using anti-NF-IL6 C-terminal antibody. Addition
of GST instead of GST-CHOP did not a¡ect the precipitated NF-
IL6 isoforms (not shown). B: A375 cells were transiently co-trans-
fected with pIL6(3231)-Luc (0.02 Wg), L-galactosidase plasmid (0.04
Wg) and the indicated constructs. The relative promoter activity indi-
cates the ratio between the luciferase activity in mock transfectants
and that in other conditions after normalization with L-galactosi-
dase activity. MeanTS.D. based on triplicate cultures is shown.
Fig. 5. Dose^response e¡ect of CHOP on the IL-6 gene transcrip-
tion. A: A375 cells were transiently co-transfected with pIL6(3231)-
Luc (0.02 Wg), L-galactosidase plasmid (0.04 Wg) and the indicated
amounts (0.02^0.4 Wg) of pcDNA3.1-Myc/hCHOP. The relative pro-
moter activity indicates the ratio between the luciferase activity in
mock transfectants and that in other conditions after normalization
with L-galactosidase activity. MeanTS.D. based on triplicate cul-
tures is shown. B: A375 cells were transiently transfected with the
indicated amounts of pcDNA3.1-Myc/CHOP. Cell extracts from
each transfectant or from cells treated with 2 Wg/ml of tunicamycin
for 6 h were analyzed by immunoblotting (IB) using anti-CHOP or
anti-L-actin antibody.
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5A, CHOP augmented IL-6 promoter activity in a dose-de-
pendent manner up to 0.2 Wg of plasmid. More than 0.2 Wg of
plasmid tended to decrease the transcriptional activity. At
high levels of CHOP expression, LIP would be completely
sequestered by CHOP, but excess CHOP would then also
make LAP unavailable for transactivation. To assess the
physiological signi¢cance of the phenomenon, we examined
the expression level of endogenous CHOP in A375 cells under
conditions of stress. The level of CHOP expression in A375
cells treated with tunicamycin is similar to the levels of trans-
fected CHOP expression that enhance IL-6 expression (equal
to transfection of 0.04^0.2 Wg plasmid) (Fig. 5A,B). These
results indicated that the endogenous CHOP level in stressed
A375 cells is not so high as to exhibit inhibition of IL-6 trans-
activation.
4. Discussion
We have previously demonstrated that CHOP up-regulated
IL-6 production at the transcriptional level, and that the leu-
cine zipper domain of CHOP is required for its activity [20].
Because CHOP could not form homodimers [19], it was sug-
gested that heterodimerization of CHOP with other C/EBP
family proteins was critical. However, the molecular mecha-
nism for CHOP-induced stimulation of IL-6 transcription was
not well understood.
Originally it had been thought that CHOP acts as an in-
hibitor for other C/EBP family proteins by forming hetero-
dimers [18]. However, IL-6 production was up-regulated and
an IL-6 reporter gene was activated when CHOP was ex-
pressed ([20], Fig. 1). Therefore, we at ¢rst thought that
CHOP up-regulated IL-6 transcription through its own tran-
scriptional activity by binding to a speci¢c motif on the IL-6
promoter region as reported by Ubeda et al. [19]. Unexpect-
edly, there was no reported CHOP binding element in the IL-
6 promoter and no binding of CHOP to the IL-6 promoter
could be demonstrated either by ChIP assay or by promoter
pull-down assays. In addition, our previous study demon-
strated that CHOP could activate the IL-6 promoter even if
the p38 mitogen-activated protein kinase-dependent phos-
phorylation site or the DNA binding domain was defective
[20]. These observations strongly suggest that CHOP activates
IL-6 promoter in a manner independent of its transcriptional
activity and interaction with IL-6 promoter DNA.
As described above, CHOP could activate IL-6 transcrip-
tion despite its inhibitory e¡ect on the transcriptional activity
of NF-IL6. Of the C/EBP family transcription factors, Ig/EBP
(C/EBPQ), ubiquitously expressed in various tissues [25,26],
and LIP (NF-IL6 3rd AUG), the translation product initiated
at the third AUG on the NF-IL6 mRNA [9,10], have been
shown to inhibit the function of C/EBP transcriptional acti-
vators by forming heterodimers and have been proposed to
act as a bu¡er against C/EBP-mediated activation. Actually,
these inhibitory C/EBPs suppressed activation of IL-6 pro-
moter induced by NF-IL6 (LAP) even in our model (data
not shown, Fig. 4B). These reports and observations sug-
gested to us the following hypothesis accounting for the mech-
anism of CHOP-mediated IL-6 promoter activation. At
steady state, these inhibitory C/EBP proteins suppress tran-
scriptional activity of NF-IL6 (LAP) by forming heterodimers
or occupying the NF-IL6 binding motif in the IL-6 promoter.
However, when CHOP is present, it sequesters the inhibitory
C/EBP proteins away from NF-IL6 (LAP) or the IL-6 pro-
moter by dimerizing with them. Consequently, homodimer
formation of NF-IL6 (LAP) and its binding to IL-6 promoter
are augmented, which leads to activation of IL-6 transcription
(Fig. 6). This hypothesis was con¢rmed in this study. In fact,
CHOP dimerized preferentially with NF-IL6 3rd AUG, the
inhibitory isoform of NF-IL6, both in vitro and in vivo. Fur-
thermore, CHOP diminished the amount of NF-IL6 3rd AUG
bound to an IL-6 promoter template, whereas NF-IL6 1st and
2nd AUG were not a¡ected. Consistent with these observa-
tions, CHOP rescued transcriptional activity of NF-IL6
down-regulated by NF-IL6 vSpl, an NF-IL6 derivative that
mimics NF-IL6 3rd AUG.
Sylvester et al. reported that during the acute phase re-
sponse induced by LPS, CHOP seemed to be induced by
newly produced NF-IL6 via a C/EBP regulatory site in the
promoter region of CHOP in rat liver or human hepatoma
cell line [27]. Similar to CHOP induction, acute phase protein
induction is temporally delayed relative to NF-IL6 induction.
In this case LPS leads to the relatively sustained induction of
acute phase proteins compared to the NF-IL6 or CHOP in-
duction. The LIP trapping e¡ect of CHOP might cause this
sustained induction.
Recently Hu et al. presented that LIP or NF-IL6 bZIP
domain can mediate LPS induction of IL-6 through NF-UB
activation in murine B lymphoblast P388 cells [28]. In our
study, however, LIP overexpression suppressed IL-6 transac-
tivation and CHOP rescued this e¡ect (Fig. 4B). Moreover,
CHOP
NF-IL6
3rd AUG
CHOP
NF-IL6
1st AUG
NF-IL6
1st AUG
IL-6
NF-IL6
1st AUG
NF-IL6
3rd AUG
IL-6
or
NF-IL6
3rd AUG
NF-IL6
3rd AUG
IL-6
Fig. 6. Proposal mechanism for IL-6 gene transcription mediated by
CHOP. A heterodimer comprising NF-IL6 1st (or 2nd) AUG and
NF-IL6 3rd AUG, or an NF-IL6 3rd AUG homodimer, occupies
the C/EBP binding element in the IL-6 promoter and therefore IL-6
transcription is inactive. CHOP may enhance IL-6 gene transcrip-
tion by sequestering the negatively regulating isoform NF-IL6 3rd
AUG away from NF-IL6 1st (or 2nd) AUG or from the C/EBP
binding element.
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NF-UB seemed to contribute little to the CHOP-dependent
IL-6 transactivation (data not shown). The expression levels
of LIP in A375, 293 and HepG2 cells are relatively low com-
pared to that of LAP. Overexpression of LIP or NF-IL6 bZIP
in P388, which probably had no LAP, resulted in a di¡erent
output. We have to consider the balance of expression levels
of LAP/LIP/CHOP in the cells. This balance might be depen-
dent on the cell types and also be changed by various stimu-
lants.
From the dose^response experiments, an optimum dose of
CHOP for the IL-6 transcription was observed. At high levels
of CHOP expression, NF-IL6 3rd AUG (LIP) would be com-
pletely sequestered by CHOP, but excess CHOP would then
also make NF-IL6 1st and 2nd AUG (LAP) unavailable for
transactivation. CHOP has been reported to be induced by
various stresses in cells. Our results transfecting CHOP ex-
pression plasmid in A375 cells suggest that the level of endog-
enous CHOP in stressed cells is enough to trap LIP but not so
high as to show the inhibition of IL-6 transactivation. These
results indicate that physiologically induced CHOP mostly
leads to augmentation of IL-6 transcription by trapping LIP.
This is a novel regulatory mechanism of CHOP on NF-IL6
function. Because NF-IL6 is responsible for activation of
many genes including cytokines (TNFK, IL-1, IL-8 and G-
CSF) and acute phase proteins (haptoglobin, CRP, K1-acid
glycoprotein) [8], CHOP may also contribute to the regulation
of those genes.
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